NHS England

Rackspace Technology Launches Rackspace UK Sovereign Services for Secure, Cost-Effective Workloads in the UK Public Sector and Regulated Services

Retrieved on: 
Wednesday, March 27, 2024
British, Government, Environment, Partnership, Pods, Law enforcement, Rackspace Technology, NHS, AI, Private sector, Pod, Disaster recovery, Evergreen, Public sector, NHS England, Police

The offering provides end-to-end, digitally sovereign cloud services for the UK public sector and other regulated industries.

Key Points: 
  • The offering provides end-to-end, digitally sovereign cloud services for the UK public sector and other regulated industries.
  • Rackspace UK Sovereign Services prioritises customer data security aligned with the recommendations of the UK National Cyber Security Centre & NHS England amongst other UK regulatory bodies.
  • This truly digital Sovereign offering allows for the UK public sector to achieve cost savings and compliance all through a single provider, without compromising on security or performance,” said Rick Martire, General Manager for Sovereign Services, UK at Rackspace Technology.
  • Rackspace UK Sovereign Services key features include:
    Fully managed end-to-end solution with a pre-built blueprint, anti-malware protection, vulnerability scanning, performance monitoring and system patching included as standard.

British Technology company, C the Signs, selected by the White House-Backed Accelerator Programme, CancerX, to half Cancer Deaths

Retrieved on: 
Tuesday, February 27, 2024
Cancer Moonshot, AstraZeneca, Intel, Atrium Health, National Health Service, Quality of life, Hope, White, Risk, Social work, NHS, Health care, UC, Business, Patient, Accelerator, Dell Technologies, NHS England, Disease, Heart, Healthcare UK, Mortality, AWS, Cancer, Pharmaceutical industry

CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.

Key Points: 
  • CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.
  • The CancerX Accelerator programme aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations.
  • C the Signs is an AI cancer prediction platform that identifies patients at risk of cancer at the earliest and most curable stage of the disease.
  • Launched by the White House, this initiative marks a significant step toward realizing the Cancer Moonshot's vision of a 50% reduction in cancer mortality.

British Technology company, C the Signs, selected by the White House-Backed Accelerator Programme, CancerX, to half Cancer Deaths

Retrieved on: 
Tuesday, February 27, 2024
Cancer Moonshot, AstraZeneca, Intel, Atrium Health, National Health Service, Quality of life, Hope, White, Risk, Social work, NHS, Health care, UC, Business, Patient, Accelerator, Dell Technologies, NHS England, Disease, Heart, Healthcare UK, Mortality, AWS, Cancer, Pharmaceutical industry

CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.

Key Points: 
  • CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.
  • The CancerX Accelerator programme aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations.
  • C the Signs is an AI cancer prediction platform that identifies patients at risk of cancer at the earliest and most curable stage of the disease.
  • Launched by the White House, this initiative marks a significant step toward realizing the Cancer Moonshot's vision of a 50% reduction in cancer mortality.

HistoSonics Awarded Key Position in UK’s Novel Innovation Program

Retrieved on: 
Wednesday, February 14, 2024
Seniors, Other Science, Radiology, Research, Oncology, Medical Devices, Hardware, Consumer, Fund Raising, Hospitals, Foundation, Philanthropy, Science, Technology, Clinical Trials, FDA, Biotechnology, Surgery, Health, IDAP, Liver, User experience, Multimedia, Neoplasm, Physician, Social work, NHS, Health care, Patient, Pancreas, MHRA, Blue, NHS England, Kidney, Medication, Partnership, Pharmaceutical industry

The Edison Histotripsy System was measured against four distinct eligibility criteria that were required of applicants for consideration in the IDAP program.

Key Points: 
  • The Edison Histotripsy System was measured against four distinct eligibility criteria that were required of applicants for consideration in the IDAP program.
  • HistoSonics' Edison System uses proprietary technology and advanced imaging to deliver personalized, non-invasive histotripsy treatments with precision and control.
  • Uniquely, the HistoSonics’ platform also provides physicians the ability to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today.
  • The Edison System is indicated for the non-invasive destruction of liver tumors, including unresectable liver tumors, using a non-thermal, mechanical process of focused ultrasound.

Hundreds of sickle cell patients to benefit from £1.5M technology investment

Retrieved on: 
Wednesday, February 14, 2024
Hospital, Mandate, Sickle cell disease, Pain, African, Cell, Spectra, Risk, NHS, Human, Patient, NHS England, Pharmaceutical industry

Investment in the rollout of this technology could provide an additional 10,000 apheresis procedures annually.

Key Points: 
  • Investment in the rollout of this technology could provide an additional 10,000 apheresis procedures annually.
  • Sickle cell patients often find themselves in and out of hospitals, enduring severe pain and requiring regular "top-up" blood transfusions.
  • I'm very proud of the role the MedTech Funding Mandate has played in the rollout of this technology to ensure we meet the automated red blood cell exchange needs of sickle cell patients."
  • Antoinette Gawin, President and CEO, Terumo Blood and Cell Technologies: "This investment helps more patients get treatment with a proven therapy to manage sickle cell disease.

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

Retrieved on: 
Thursday, February 8, 2024
Alimera Sciences, Visual impairment, NHS Wales, News, Patient, Recurrence, Physician, NHS, Disease, Fluocinolone acetonide, DME, NHS England, Pharmaceutical industry

“This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.

Key Points: 
  • “This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.
  • We look forward to the publication of Final Guidance shortly.”
    NICE is recommending on label access to ILUVIEN as an option for treating visual impairment caused by chronic DME in phakic eyes.
  • NHS England has agreed with the Integrated Care Boards (ICB’s) to provide funding to implement this guidance 30 days after publication.
  • NHS Wales will usually fund within 2 months of the final draft guidance.

Accord Healthcare partners with ITN Business for World Cancer Day to explore how innovative approaches are helping shape the future of cancer care

Retrieved on: 
Sunday, February 4, 2024
Partnership, MHRA, Patient, Intas Pharmaceuticals, Accord, Diagnosis, NHS, Disease, NHS England, Cancer, Medical imaging

The reality is every two minutes someone in the UK is diagnosed with cancer, with 1 in 2 people being diagnosed with some form of cancer during their lifetime[1].

Key Points: 
  • The reality is every two minutes someone in the UK is diagnosed with cancer, with 1 in 2 people being diagnosed with some form of cancer during their lifetime[1].
  • The programme also highlights how Accord has played a leading role in partnership with NHS England and MHRA to repurpose older medicines to help new cohorts of patients.
  • "With so many of us affected by cancer, this has been a really important and poignant programme to be part of.
  • Only through collaboration between cancer experts, industry, academia and patient organizations, can we make real progress toward a world without cancer.

UK Healthcare Temporary Recruitment and Staffing Report: The Emergence of Insourcing as an Alternative Service Delivery Model

Retrieved on: 
Thursday, January 18, 2024
Workforce, Hope, NHS, Health care, NHS England, Policy

DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The "Temporary Recruitment and Staffing: Healthcare 1ed" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The "Temporary Recruitment and Staffing: Healthcare 1ed" report has been added to ResearchAndMarkets.com's offering.
  • The first edition of Temporary Recruitment and Staffing: Healthcare - UK market landscape report is vital reading for anyone involved in this highly competitive sector of the UK health economy, be they investors, lenders, those offering staffing solutions or strategic leads for workforce planning in healthcare providers.
  • The market landscape report takes stock of the recruitment agency market for temporary healthcare staff against a backdrop of rapidly rising expenditure on non-permanent staffing solutions, following several years of relatively tight fiscal control.
  • In total, the temporary healthcare recruitment agency market is valued at £5.1 billion across the healthcare sector, with a 11.8% CAGR over the last five years.

Accelerated Access to GP Records (AAGPR) DPIA's response

Retrieved on: 
Friday, January 19, 2024
Roger Hawkins (drummer), Program, GP, NHS England, ICO

Over recent weeks, a number of Data Protection Impact Assessments (DPIAs) have been submitted by GP Practices.

Key Points: 
  • Over recent weeks, a number of Data Protection Impact Assessments (DPIAs) have been submitted by GP Practices.
  • The subject of the DPIAs is the implementation of the Accelerated Access to GP Records (AAGPR) program developed by NHS England as a method for individuals to obtain their medical records from GPs.
  • As the DPIAs submitted are largely similar in style and content, the ICO has chosen to make the contents of the response publicly available so GPs affected are aware of the ICO’s views on the matter.

BIOS Health Plans State-of-the-Art Precision Medicine Center in Bakersfield, California

Retrieved on: 
Monday, January 8, 2024
Software, Research, Pharmaceutical, Data Management, Medical Devices, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Neurology, Health, Community development, Entrepreneurship, Ecosystem, Medicine, NHS England, Multimedia, City, DNA, Manager, Clinical trial, News, Stanford University, AI, University, Mayo Clinic, Economic development, Bangladesh Technical Education Board, Interim, Growth, NIH, Patient, NHS, KVG, Clinical professor, Partner (business rank), Pharmaceutical industry

BIOS Health announced today it is partnering with the City of Bakersfield, Kern County, and Kern Venture Group (KVG) to establish a state-of-the-art precision medicine center in Bakersfield, California.

Key Points: 
  • BIOS Health announced today it is partnering with the City of Bakersfield, Kern County, and Kern Venture Group (KVG) to establish a state-of-the-art precision medicine center in Bakersfield, California.
  • BIOS Health is pioneering the technology to read and interpret neural signals in real-time with AI, giving crucial insights previously inaccessible to clinicians, and pharmaceutical and medical device companies.
  • BIOS will establish its West Coast hub to serve as the premier center for neural clinical trials and R&D, and to accelerate its broader commercialization in the US market.
  • Emil Hewage, CEO of BIOS Health, said: “We are excited to be creating the infrastructure, alongside our regional, clinical and commercial partners, to deliver a new future for precision medicine development.